Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

14 Dec 2021

Abstract excerpt

International audience

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium signaling and nucleotide metabolism
Share to Multiple Myeloma Research and Treatments
Share to SARS-CoV-2 and COVID-19 Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34905598
DOI: 10.1182/blood.2021013714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myelomaPMID 34905598Read ↗

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patientsSemantic proximity Read ↗

Cellular Mechanisms Associated with Sub-Optimal Immune Responses to SARS-CoV-2 Bivalent Booster Vaccination in Patients with Multiple MyelomaSemantic proximity Read ↗

Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.Semantic proximity Read ↗

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patientsSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity Read ↗

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read ↗

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity Read ↗

SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicitySemantic proximity Read ↗

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaSemantic proximity Read ↗

Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patientsSemantic proximity Read ↗

Current status of therapeutic monoclonal antibodies against SARS-CoV-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.